Biopharmaceuticals
News Release - June 2, 2011
GSK and Theravance Announce Results of Two Pivotal Phase III Studies for Relovair(TM) in COPD
Source: Theravance
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.